InvestorsHub on MSN
BioAffinity Technologies receives Japanese patent allowance for CyPath Lung AI diagnostic test
The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive ...
Why I built thisIsn't it hard to find information on CDx?When working in a pathology laboratory, clinicians sometimes ask ...
Hello! I'm Nao, and I attend Carol Davila University of Medicine and Pharmacy in Romania 🇷🇴The long summer vacation is over, and classes for my second year of medical school have finally ...
Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado Anschutz School of Medicine ...
Glioma brain tumors are diffuse, so surgeons usually cannot excise all of the cancer during surgery. Currently, surgeons ...
A new review warns that the molecular tests defining modern glioma diagnosis remain out of reach for most of the world, and ...
Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.
SOPHiA GENETICS develops healthcare analytics using genomics, artificial intelligence and multimodal data across clinical and life-science applications.
Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado Anschutz School of Medicine ...
Gastric cancer remains one of the world’s most lethal malignancies. According to GLOBOCAN 2022 estimates, stomach cancer ...
Affinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today ...
The superbug fight is moving into the pathology lab, and Clever Culture could have useful tech sitting right in the ... Read More The post AI is joining the superbug fight and ASX investors should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results